BioStem Technologies (OTCMKTS:BSEM) Shares Down 4.8% - Here's What Happened

Key Points

• BioStem Technologies shares fell 4.8% mid-day Monday, trading as low as $4.52 and last at $4.60, with 53,898 shares changing hands—about 10% below average volume.
• Zacks Research upgraded the stock to a Hold, and MarketBeat shows a consensus rating of Hold based on one analyst.
• The company has a market capitalization of $78.11 million and a negative P/E of -10.85, with the 50-day and 200-day moving averages at $5.11 and $4.86, respectively.

BioStem Technologies, Inc. (OTCMKTS:BSEM - Get Free Report) fell 4.8% during mid-day trading on Monday . The company traded as low as $4.52 and last traded at $4.60. 53,898 shares traded hands during trading, a decline of 10% from the average session volume of 59,805 shares. The stock had previously closed at $4.83.

Wall Street Analyst Weigh In

Separately, Zacks Research upgraded shares of BioStem Technologies to a "hold" rating in a report on Wednesday, March 18th. One analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, the company has a consensus rating of "Hold".

BioStem Technologies Stock Performance

The company has a market capitalization of $78.11 million and a P/E ratio of -10.85. The stock has a 50 day moving average price of $5.11 and a 200 day moving average price of $4.86.

About BioStem Technologies

BioStem Technologies, Inc, a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding supplies; and develops and markets nutraceutical products under the Dr.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.